The financials
Vertex Pharmaceuticals by the numbers
Vertex Pharmaceuticals (VRTX) reported revenue of $3.33B in Q2 2026 (quarter ended Jun 30, 2026), up 12% from the same quarter a year earlier. That came with a gross margin of 85% and net income of $1.10B (33% of revenue). For the full year FY2025, revenue was $12.0B (+8.9% year on year) and net income $3.95B. Its largest product in Q2 2026 was TRIKAFTAKAFTRIO at $2.50B, 75% of the disclosed total, well ahead of ALYFTREK at 17%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $3.33B | $2.96B | +12% |
| Gross profit | $2.84B | $2.56B | +11% |
| Operating income | $1.25B | $1.15B | +8.3% |
| Net income | $1.10B | $1.03B | +6.5% |
| Diluted EPS | $4.31 | $3.99 | +8.0% |
| Product | Revenue | Share |
|---|---|---|
| TRIKAFTAKAFTRIO | $2.50B | 75% |
| ALYFTREK | $574M | 17% |
| Manufactured Product Other | $137M | 4.1% |
| CASGEVY | $76M | 2.3% |
| JOURNAVX | $50M | 1.5% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $3.33B (+12%)
JOURNAVX grew +313% year on yearCollaborative and Royalty -100% year on year
Segment Latestquarter on quarteryear on year
- TRIKAFTAKAFTRIO$2.50B$2.50BQoQ +6.1%year on year -2.1%+6.1%-2.1%
- ALYFTREK$573.6M$573.6MQoQ +35%year on year +266%+35%+266%
- Manufactured Product Other$137.1M$137.1MQoQ +0.88%year on year -29%+0.88%-29%
- CASGEVY$76.4M$76.4MQoQ +78%year on year +151%+78%+151%
- JOURNAVX$49.6M$49.6MQoQ +71%year on year +313%+71%+313%
- Collaborative and Royalty$0.00$0.00QoQ -year on year -100%--100%
Biotechnology
The closest names by size in the same industry